Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2022 Oct;62(10):2117-2136.
doi: 10.1111/trf.17064. Epub 2022 Aug 20.

Prophylactic platelet transfusions versus no prophylaxis in hospitalized patients with thrombocytopenia: A systematic review with meta-analysis

Carl Thomas Anthon  1 , Anders Granholm  1 , Praleene Sivapalan  1 , Núria Zellweger  2 , Frédéric Pène  3 , Kathryn Puxty  4 , Anders Perner  1   5 , Morten Hylander Møller  1   5 , Lene Russell  1   5
Affiliations
Meta-Analysis

Prophylactic platelet transfusions versus no prophylaxis in hospitalized patients with thrombocytopenia: A systematic review with meta-analysis

Carl Thomas Anthon et al. Transfusion. 2022 Oct.
No abstract available

Keywords: adverse effects; bleeding; mortality; platelet transfusion; thrombocytopenia.

PubMed Disclaimer

Conflict of interest statement

The Department of Intensive Care at Rigshospitalet (CA, AG, PS, MHM, AP, and LR) has received funding for other projects from the Novo Nordisk Foundation, Pfizer, Sygeforsikringen “danmark” and Fresenius Kabi and conducts contract research for AM‐Pharma. FP has received personal fees from Gilead and an institutional grant from Alexion for other projects. KP and NZ have no conflict of interests.

Figures

FIGURE 1
FIGURE 1
Flowchart of the trial selection process. One ongoing trial is awaiting classification due to insufficient information on the trial population.
FIGURE 2
FIGURE 2
Forest plot for the primary outcome all‐cause mortality at longest follow‐up in all trials
FIGURE 3
FIGURE 3
Forest plot for the secondary outcome clinically important bleeding (as defined in the included trials) at longest follow‐up. Data from Wandt 2012 were reported per treatment cycle and only data for a subgroup of patients who had undergone autologous transplantation was extractable.
FIGURE 4
FIGURE 4
Trial sequential analyses (TSA) plot for the secondary outcome clinically important bleeding using a control event rate of 45.2% (from the included trials), a diversity D 2 of 72%, an alpha of 2.5%, a beta of 0.1 and a relative risk (RR) reduction of 15%. The meta‐analytic RR was 0.70 with a TSA adjusted confidence interval of 0.26 to 1.87. The required information size was not reached (13.7% acquired) and the trial monitoring boundaries or futility boundaries were not crossed. Hence, the TSA highlights that the accrued information size was insufficient to reject or confirm a 15% reduction in RR. [Color figure can be viewed at wileyonlinelibrary.com]
See this image and copyright information in PMC

References

    1. Ten Berg MJ, Van Den Bemt PMLA, Shantakumar S, Bennett D, Voest EE, Huisman A, et al. Thrombocytopenia in adult cancer patients receiving cytotoxic chemotherapy: results from a retrospective hospital‐based cohort study. Drug Saf. 2011;34(12):1151–60. - PubMed
    1. Shaw JL, Nielson CM, Park JK, Marongiu A, Soff GA. The incidence of thrombocytopenia in adult patients receiving chemotherapy for solid tumors or hematologic malignancies. Eur J Haematol. 2021;106(5):662–72. - PMC - PubMed
    1. Afdhal N, McHutchison J, Brown R, Jacobson I, Manns M, Poordad F, et al. Thrombocytopenia associated with chronic liver disease. J Hepatol. 2008;48:1000–7. - PubMed
    1. Sparger K, Deschmann E, Sola‐Visner M. Platelet transfusions in the neonatal intensive care unit. Clin Perinatol. 2015;42:613–23. - PMC - PubMed
    1. Hui P, Cook DJ, Lim W, Fraser GA, Arnold DM. The frequency and clinical significance of thrombocytopenia complicating critical illness: a systematic review. Chest. 2011;139(2):271–8. - PubMed

Publication types